The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like ...

Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.

As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...

Shaperon secures phase 2 trials for atopic dermatitis treatment Nugel after positive review Shaperon obtains approval for ...

Read on to learn more about the types and symptoms of dermatitis. This article also looks at causes, treatment options, and more. Atopic dermatitis, or eczema, can run in families, and usually ...

Shaperon successfully completed part 1 of the multinational phase 2 clinical trial of 'HY209 gel' targeting patients with ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Tofacitinib etocomil ointment 1.0% has proven effective in treating mild-to-moderate atopic dermatitis, achieving significant ...

Technoderma Medicines, Inc. ('the Company'), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...